In this final episode, Migvis Monduy, MD, discussed long-term data needed to define vamorolone’s durability, safety, and impact across disease stages, including unanswered questions around bone health, growth, cardiomyopathy, and combination strategies.
A forward-looking discussion on the continued role of vamorolone as background steroid therapy in patients receiving gene or mutation-specific treatments, including what is known, what remains uncertain, and how clinicians are navigating combination strategies in practice.
A practical discussion on how vamorolone is being incorporated into Duchenne management, including its role in steroid initiation, reintroduction after prior intolerance, and long-term planning across different stages of disease.
A closer look at how LIONHEART and VISION-DMD reinforce vamorolone’s distinct profile in Duchenne muscular dystrophy
Migvis Monduy, MD, provided clinical perspective on how vamorolone compares with traditional corticosteroids and why its safety profile matters in long-term Duchenne management.
